BioGend shares hit limit after RevoCart global IP buyout

The company signed an assignment agreement with ITRI and NTUH, gaining full worldwide rights to its autologous cartilage repair product and removing constraints tied to the earlier licensing structure.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.